148 related articles for article (PubMed ID: 26669863)
21. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.
Ahmed N; Abubaker K; Findlay J; Quinn M
J Cell Biochem; 2013 Jan; 114(1):21-34. PubMed ID: 22887554
[TBL] [Abstract][Full Text] [Related]
22. SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
Yang M; Xie X; Ding Y
Oncol Rep; 2016 Mar; 35(3):1796-806. PubMed ID: 26750614
[TBL] [Abstract][Full Text] [Related]
23. Putative stem cells and epithelial-mesenchymal transition revealed in sections of ovarian tumor in patients with serous ovarian carcinoma using immunohistochemistry for vimentin and pluripotency-related markers.
Kenda Suster N; Smrkolj S; Virant-Klun I
J Ovarian Res; 2017 Feb; 10(1):11. PubMed ID: 28231820
[TBL] [Abstract][Full Text] [Related]
24. High level of CFTR expression is associated with tumor aggression and knockdown of CFTR suppresses proliferation of ovarian cancer in vitro and in vivo.
Xu J; Yong M; Li J; Dong X; Yu T; Fu X; Hu L
Oncol Rep; 2015 May; 33(5):2227-34. PubMed ID: 25738998
[TBL] [Abstract][Full Text] [Related]
25. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
[TBL] [Abstract][Full Text] [Related]
26. DDB2 represses ovarian cancer cell dedifferentiation by suppressing ALDH1A1.
Cui T; Srivastava AK; Han C; Wu D; Wani N; Liu L; Gao Z; Qu M; Zou N; Zhang X; Yi P; Yu J; Bell EH; Yang SM; Maloney DJ; Zheng Y; Wani AA; Wang QE
Cell Death Dis; 2018 May; 9(5):561. PubMed ID: 29752431
[TBL] [Abstract][Full Text] [Related]
27. Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells.
Winterhoff BJ; Maile M; Mitra AK; Sebe A; Bazzaro M; Geller MA; Abrahante JE; Klein M; Hellweg R; Mullany SA; Beckman K; Daniel J; Starr TK
Gynecol Oncol; 2017 Mar; 144(3):598-606. PubMed ID: 28111004
[TBL] [Abstract][Full Text] [Related]
28. Cancer Stem Cell-Related Marker NANOG Expression in Ovarian Serous Tumors: A Clinicopathological Study of 159 Cases.
Kenda Šuster N; Frković Grazio S; Virant-Klun I; Verdenik I; Smrkolj Š
Int J Gynecol Cancer; 2017 Nov; 27(9):2006-2013. PubMed ID: 28906309
[TBL] [Abstract][Full Text] [Related]
29. Emerging Role of Nestin as an Angiogenesis and Cancer Stem Cell Marker in Epithelial Ovarian Cancer: Immunohistochemical Study.
Osman WM; Shash LS; Ahmed NS
Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):571-580. PubMed ID: 26945442
[TBL] [Abstract][Full Text] [Related]
30. Fusion-derived epithelial cancer cells express hematopoietic markers and contribute to stem cell and migratory phenotype in ovarian carcinoma.
Ramakrishnan M; Mathur SR; Mukhopadhyay A
Cancer Res; 2013 Sep; 73(17):5360-70. PubMed ID: 23856249
[TBL] [Abstract][Full Text] [Related]
31. The inhibitory effect of hypoxic cytotoxin on the expansion of cancer stem cells in ovarian cancer.
Nozawa-Suzuki N; Nagasawa H; Ohnishi K; Morishige K
Biochem Biophys Res Commun; 2015 Feb; 457(4):706-11. PubMed ID: 25619133
[TBL] [Abstract][Full Text] [Related]
32. MiR-628-5p decreases the tumorigenicity of epithelial ovarian cancer cells by targeting at FGFR2.
Li M; Qian Z; Ma X; Lin X; You Y; Li Y; Chen T; Jiang H
Biochem Biophys Res Commun; 2018 Jan; 495(2):2085-2091. PubMed ID: 29229394
[TBL] [Abstract][Full Text] [Related]
33. In vitro enrichment of ovarian cancer tumor-initiating cells.
House CD; Hernandez L; Annunziata CM
J Vis Exp; 2015 Feb; (96):. PubMed ID: 25742116
[TBL] [Abstract][Full Text] [Related]
34. High ALDH activity defines ovarian cancer stem-like cells with enhanced invasiveness and EMT progress which are responsible for tumor invasion.
Li Y; Chen T; Zhu J; Zhang H; Jiang H; Sun H
Biochem Biophys Res Commun; 2018 Jan; 495(1):1081-1088. PubMed ID: 29170132
[TBL] [Abstract][Full Text] [Related]
35. Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells.
Zhang R; Zhang P; Wang H; Hou D; Li W; Xiao G; Li C
Stem Cell Res Ther; 2015 Dec; 6():262. PubMed ID: 26718286
[TBL] [Abstract][Full Text] [Related]
36. CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma.
Bartakova A; Michalova K; Presl J; Vlasak P; Kostun J; Bouda J
J Obstet Gynaecol; 2018 Jan; 38(1):110-114. PubMed ID: 28816557
[TBL] [Abstract][Full Text] [Related]
37. The STAT3-miRNA-92-Wnt Signaling Pathway Regulates Spheroid Formation and Malignant Progression in Ovarian Cancer.
Chen MW; Yang ST; Chien MH; Hua KT; Wu CJ; Hsiao SM; Lin H; Hsiao M; Su JL; Wei LH
Cancer Res; 2017 Apr; 77(8):1955-1967. PubMed ID: 28209618
[TBL] [Abstract][Full Text] [Related]
38. Modelling genetic and clinical heterogeneity in epithelial ovarian cancers.
Lawrenson K; Sproul D; Grun B; Notaridou M; Benjamin E; Jacobs IJ; Dafou D; Sims AH; Gayther SA
Carcinogenesis; 2011 Oct; 32(10):1540-9. PubMed ID: 21859834
[TBL] [Abstract][Full Text] [Related]
39. LGR4 maintains HGSOC cell epithelial phenotype and stem-like traits.
Wang Z; Yin P; Sun Y; Na L; Gao J; Wang W; Zhao C
Gynecol Oncol; 2020 Dec; 159(3):839-849. PubMed ID: 32980127
[TBL] [Abstract][Full Text] [Related]
40. Characterization of aldehyde dehydrogenase 1 high ovarian cancer cells: Towards targeted stem cell therapy.
Sharrow AC; Perkins B; Collector MI; Yu W; Simons BW; Jones RJ
Gynecol Oncol; 2016 Aug; 142(2):341-8. PubMed ID: 27017984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
